Targeting Tumors Based on a Biomarker
The FDA approved the first cancer treatment for use based on the tumor having certain biomarkers and not where in the body the tumor originated.
Progress Against Cancer
The FDA approved the first cancer treatment for use based on the tumor having certain biomarkers and not where in the body the tumor originated.
The FDA approved an immune checkpoint inhibitor – a type of immunotherapy – to treat certain patients with bladder cancer.
The FDA has approved a new immune checkpoint inhibitor, durvalumab, for the treatment of certain bladder cancer patients.
A decrease in a specific population of circulating tumor cells over two months of crizotinib treatment associated with progression-free survival.
A study describes a biomarker to predict immunotherapy response early in the course of treatment and a noninvasive imaging method to detect this biomarker.
A study connects alcohol consumption with an increased risk of most types of breast cancer among African-American women. For the past decade, researchers have known that alcohol raises the risk of breast cancer. But...
The FDA expanded the use of regorafenib to treat certain patients with the most common form of liver cancer diagnosed in the U.S. – hepatocellular carcinoma.
The FDA approved a molecularly targeted therapeutic for the maintenance treatment of patients with recurrent epithelial ovarian and other cancers.
The FDA issued the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma.
The FDA expanded the use of the immunotherapeutic pembrolizumab to include the treatment of certain patients with Hodgkin lymphoma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More